Purpose: A relative deficiency of plasminogen within the thrombus may be the rate limiting factor in clot lysis. Methods: To investigate this hypothesis, we used an in vitro perfusion system and expanded polytetrafluoroethylene graft segments filled with radiolabeled human thrombus. Three groups of five perfusions were compared: (1) urokinase infusion (333 IU/min) into clots laced with buffer, (2) urokinase infusion (333 IU/min) into clots laced with plasminogen (44 CU), and (3) control, D5W infusion into clots laced with buffer. Two end points were measured over time: the amount of lysed thrombus and the flow through the graft. Results: Urokinase infusion resulted in augmented flow through the graft when compared with control ( p < 0.05). Lacing with plasminogen resulted in more rapid restoration of flow when compared with urokinase infusion alone ( p < 0.05). Similarly, the rate of clot dissolution was significantly greater in plasminogen-laced thrombi ( p < 0.05) when compared with the control and urokinase groups. Embolization of particles of thrombus was uniformly observed in the urokinase group, resulting in a temporary decrease in flow through the thrombosed graft. This event characteristically occurred after 60 minutes of infusion but was never seen in the urokinase/plasminogen treatment group. Conclusions: These results suggest that plasminogen supplementation of urokinase thrombolysis may result in significant clinical benefits with respect to the rate of clot lysis and the uniformity of clot dissolution with a lower likelihood of secondary embolization. (J VASC SURG 1994;19:298-305.) © 1994, Society for Vascular Surgery and International Society for Cardiovascular Surgery, North American Chapter. All rights reserved.
Stoughton, J., Ouriel, K., Shortell, C. K., Cho, J. S., & Marder, V. J. (1994). Plasminogen acceleration of urokinase thrombolysis. Journal of Vascular Surgery, 19(2), 298–305. https://doi.org/10.1016/S0741-5214(94)70105-9